Litcius/Paper detail

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials

Joon Hyung Kim, John Diaz‐Decaro, Ning Jiang, Shinn‐Jang Hwang, Eun Ju Choo, Maribel Miranda Co, Andrew Hastie, David S.C. Hui, Junya Irimajiri, Jacob Lee, Edward Leung, Haïwen Tang, Tomomi Tsuru, Philip Watson, Zhenhua Wu, Chong‐Jen Yu, Yanfei Yuan, Toufik Zahaf, Anthony L. Cunningham, Anne Schuind

2021Human Vaccines & Immunotherapeutics17 citationsDOIOpen Access PDF

Abstract

is a trademark owned by or licensed to the GSK group of companies.

Topics & Concepts

MedicineReactogenicityPostherpetic neuralgiamyalgiaPopulationPlaceboAdverse effectRandomized controlled trialConfidence intervalPediatricsInternal medicineAnesthesiaImmunologyImmunogenicityEnvironmental healthPathologyNeuropathic painAlternative medicineImmune systemHerpesvirus Infections and TreatmentsVector-borne infectious diseasesBartonella species infections research
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials | Litcius